GlycoMimetics Inc (GLYC)
1.64
-0.07
(-4.09%)
USD |
NASDAQ |
Apr 26, 16:00
1.78
+0.14
(+8.54%)
After-Hours: 20:00
GlycoMimetics Net Income (Quarterly): -9.079M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.079M |
| September 30, 2023 | -9.202M |
| June 30, 2023 | -8.259M |
| March 31, 2023 | -10.36M |
| December 31, 2022 | -10.24M |
| September 30, 2022 | -8.524M |
| June 30, 2022 | -13.27M |
| March 31, 2022 | -14.65M |
| December 31, 2021 | -17.42M |
| September 30, 2021 | -17.33M |
| June 30, 2021 | -14.40M |
| March 31, 2021 | -14.27M |
| December 31, 2020 | -15.56M |
| September 30, 2020 | -13.72M |
| June 30, 2020 | -14.08M |
| March 31, 2020 | -7.663M |
| December 31, 2019 | -14.73M |
| September 30, 2019 | -13.25M |
| June 30, 2019 | -15.83M |
| March 31, 2019 | -14.08M |
| December 31, 2018 | -13.91M |
| September 30, 2018 | -11.58M |
| June 30, 2018 | -11.28M |
| Date | Value |
|---|---|
| March 31, 2018 | -11.51M |
| December 31, 2017 | -9.258M |
| September 30, 2017 | -7.950M |
| June 30, 2017 | -8.142M |
| March 31, 2017 | -7.931M |
| December 31, 2016 | -8.329M |
| September 30, 2016 | -7.855M |
| June 30, 2016 | -8.072M |
| March 31, 2016 | -7.555M |
| December 31, 2015 | -8.882M |
| September 30, 2015 | -7.168M |
| June 30, 2015 | 10.39M |
| March 31, 2015 | -7.109M |
| December 31, 2014 | -7.394M |
| September 30, 2014 | -6.618M |
| June 30, 2014 | 7.992M |
| March 31, 2014 | -5.102M |
| December 31, 2013 | -3.867M |
| September 30, 2013 | -3.701M |
| June 30, 2013 | -3.497M |
| March 31, 2013 | 0.4597M |
| December 31, 2012 | 0.638M |
| September 30, 2012 | 0.8226M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-17.42M
Minimum
Dec 2021
-7.663M
Maximum
Mar 2020
-12.73M
Average
-13.72M
Median
Sep 2020
Net Income (Quarterly) Benchmarks
| Altimmune Inc | -31.64M |
| Cellectar Biosciences Inc | -7.449M |
| PDS Biotechnology Corp | -10.90M |
| Syros Pharmaceuticals Inc | -64.38M |
| Precision BioSciences Inc | -16.29M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.01M |
| Total Expenses (Quarterly) | 9.600M |
| EPS Diluted (Quarterly) | -0.14 |
| Enterprise Value | 63.91M |
| Profit Margin (Quarterly) | -90.79K% |
| Earnings Yield | -35.37% |
| Normalized Earnings Yield | -35.37 |